Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
RCT (n=1,595) found semaglutide was superior to placebo for weight reduction at 68 weeks (-9.6% vs -3.4% bodyweight, p<0.0001), and achievement of 5% weight loss (68.8% vs 28.5%, OR 4.88, p<0.0001). GI adverse events were more frequent with semaglutide (63.5% vs 34.3%).
Source:
The Lancet
SPS commentary:
A related commentary assesses the results of this study and concludes that although the effectiveness profile of semaglutide is still being fully defined, it appears that semaglutide offers the advantage of being given once a week rather than daily, with possibly higher efficacy on weight loss than liraglutide.